New China Drug Markets Research Reports by CRI Now Available at MarketPublishers.com

23 Jun 2015 • by Natalie Aster

LONDON – TD The Market Publishers, Ltd. is pleased to inform that new Chinese drug market studies developed by China Research and Intelligence Co., Ltd. (CRI) have been added to its catalogue.

Investigation Report on China Capecitabine Market, 2010-2019. In 2001, capecitabine enter the Chinese market. It was used to treat colorectal cancer, advanced breast cancer, etc. Its annual sales value almost hit the CNY 100 million mark in 2005, while it amounted to more than CNY 633 million in 2014. At present, there are five major manufacturers of the drug in the country, with one of them (Shanghai Roche Pharmaceutical Co.) holding the largest market share of 95 percent. The research report offers a comprehensive guide to the capecitabine market in China. It contains a detailed market outlook including data on market sizing…

Investigation Report on China Celecoxib Market, 2010-2019. Celebrex has been available in China since 2000 when it received approval from CFDA to enter the local marketplace. In 2004, its annual sales were estimated at no more than CNY 20 million. Currently, the Chinese market includes two top players, with Pfizer being the largest one. The research report offers an up-close look at the Chinese market for celebrex. It provides a through overview of the marketplace. The study uncovers a size of the market, investigates the competitive landscape and includes top players’ profiles. The report explores price and sales trends, forecasts future development of the market …

Investigation Report on China Desloratadine Market, 2010-2019. As of 2005, sales of desloratadine amounted to approximately CNY 12 million. Since then, they grew at a CAGR of around 36 percent annually and they reached CNY 185 million in 2014. Hairui Pharmaceutical is the top market player with a market share of more than 53 percent. The local demand for the drug is set to continue increasing in the years to come, thus driving the market growth. The research study draws up a detailed picture of the Chinese desloratadine market. It provides an in-depth overview of the market place and unveils information on the market sizing…

Investigation Report on China Doxofylline Market, 2010-2019. In 2010, annual sales of doxofylline reached a value of CNY 124 million in China. They posted annual growth of up to 15.9 percent since then to hit the CNY 224 million mark in 2014. The drug can boast high demand in the country. At present, there are more than 5 prominent players in the local marketplace, and Fuhe Huaxing Pharmaceutical Shares Co. is a leading one. The research report offers a bird’s eye view of the Chinese market for doxofylline. The study comprises a thorough overview of the market, valuable details on the competitive landscape and sales data…

More new research studies by the publisher can be found at CRI page

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com 
MarketPublishers.com